Clinical and molecular biological study of respiratory infection

Group leader: Stephen Gillespie

Sir James Black Chair of Medicine

Research overview

Stephen Gillespie has worked in Kenya researching the relationship between malaria and lower respiratory tract infection and the prevalence of parasitic infection in children in Kilifi, Kenya. He has investigated a cholera epidemic and vaccine failures in Guerrero, Mexico. He has been working in collaboration with colleagues at Kilimanjaro Christian Medical Centre since 1988 where he has, variously, studied respiratory and parasite diagnostics and novel antimalarials, anti-helminthics and anti tuberculosis agents. His main research activity is in the area of tuberculosis drug development.

For the last twenty years Stephen Gillespie has been involved in various aspects of  tuberculosis drug development. This has included the evaluation of new candidate antituberculosis agents in vitro. This work has expanded into studies of the molecular mechanisms of resistance and the development of model systems to measure the fitness deficits found in resistant strains. He has been involved in the development of fluoroquinolones for tuberculosis having performed early bacterial activity studies and clinical trials of ciprofloxacin. More recently he has led the group working on the clinical development of moxifloxacin in collaboration with the Global Alliance for TB Drug Development as Chief Investigator of the REMox TB study. He is also one of the three Chief Investigators of the PanACEA consortium that is developing Europe and Africa's clinical trials capacity.

Publications

Aarnoutse, RE, Kibiki, GS, Reither, K, Semvua, HH, Haraka, F, Mtabho, CM, Mpagama, SG, van den Boogaard, J, Sumari-de Boer, IM, Magis-Escurra, C, Wattenberg, M, Logger, JGM, te Brake, LHM, Hoelscher, M, Gillespie, SH, Colbers, A, Phillips, PPJ, Plemper van Balen, G, Boeree, MJ & PanACEA Consortium 2017, 'Pharmacokinetics, tolerability, and bacteriological response of rifampin administered at 600, 900, and 1,200 milligrams daily in patients with pulmonary tuberculosis' Antimicrobial Agents and Chemotherapy, vol 61, no. 11, e01054-17. DOI: 10.1128/AAC.01054-17
Murphy, ME, Phillips, PPJ, Mendel, CM, Bongard, E, Bateson, ALC, Hunt, R, Murthy, S, Singh, KP, Brown, M, Crook, AM, Nunn, AJ, Meredith, SK, Lipman, M, McHugh, TD, Gillespie, SH & on behalf of the REMoxTB Consortium 2017, 'Spot sputum samples are at least as good as early morning samples for identifying Mycobacterium tuberculosis' BMC Medicine, vol 15, 192. DOI: 10.1186/s12916-017-0947-9

Overview

Overview header image

Scientists associated with the thirty-two research groups that are affiliated with the Biomedical Sciences Research Complex perform highly innovative, multi-disciplinary research in eleven broad areas of biomedical research, employing state-of-the-art techniques to address key questions at the leading edge of the biomedical and biological sciences. The BSRC is grateful for funding from all funding agencies including the Institutional Strategic Support Fund from the Wellcome Trust.

Follow the links on the left to view individual research groups associated with one or more of the eleven BSRC research areas.

Research areas

Scientists associated with the thirty-two research groups that are affiliated with the Biomedical Sciences Research Complex perform highly innovative, multi-disciplinary research in eleven broad areas of biomedical research, employing state-of-the-art techniques to address key questions at the leading edge of the biomedical and biological sciences.

Follow the links on the left to view individual research groups associated with one or more of the eleven BSRC research areas.

Research by academic schools

Research in the BSRC is conducted by thirty-two independent research groups based in the Schools of Biology, Chemistry, Physics and Astronomy, and Medicine. Follow the links on the left to view groups associated with each school.